JP2021522839A5 - - Google Patents
Info
- Publication number
- JP2021522839A5 JP2021522839A5 JP2020564137A JP2020564137A JP2021522839A5 JP 2021522839 A5 JP2021522839 A5 JP 2021522839A5 JP 2020564137 A JP2020564137 A JP 2020564137A JP 2020564137 A JP2020564137 A JP 2020564137A JP 2021522839 A5 JP2021522839 A5 JP 2021522839A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- approximately
- cell
- subset
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024067406A JP2024096956A (ja) | 2018-05-14 | 2024-04-18 | 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862671358P | 2018-05-14 | 2018-05-14 | |
| US62/671,358 | 2018-05-14 | ||
| PCT/US2019/032318 WO2019222293A1 (en) | 2018-05-14 | 2019-05-14 | Subsets of human natural killer cells with enhanced antibody-directed immune responses |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067406A Division JP2024096956A (ja) | 2018-05-14 | 2024-04-18 | 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021522839A JP2021522839A (ja) | 2021-09-02 |
| JP2021522839A5 true JP2021522839A5 (enExample) | 2022-05-19 |
Family
ID=68541145
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020564137A Pending JP2021522839A (ja) | 2018-05-14 | 2019-05-14 | 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット |
| JP2024067406A Pending JP2024096956A (ja) | 2018-05-14 | 2024-04-18 | 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024067406A Pending JP2024096956A (ja) | 2018-05-14 | 2024-04-18 | 増強された抗体指向性免疫応答を有するヒトナチュラルキラー細胞のサブセット |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210187025A1 (enExample) |
| EP (2) | EP4474391A3 (enExample) |
| JP (2) | JP2021522839A (enExample) |
| CN (1) | CN112839666A (enExample) |
| AU (1) | AU2019271146A1 (enExample) |
| CA (1) | CA3099806A1 (enExample) |
| DK (1) | DK3793573T3 (enExample) |
| ES (1) | ES2993360T3 (enExample) |
| PT (1) | PT3793573T (enExample) |
| WO (1) | WO2019222293A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10066207B2 (en) | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| KR20230088306A (ko) * | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법 |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| KR20240024048A (ko) * | 2021-04-08 | 2024-02-23 | 아티바 바이오테라퓨틱스, 인크. | Nk 세포와 her2 표적 항체를 이용한 암 치료 방법 |
| AU2022254978A1 (en) | 2021-04-08 | 2023-11-16 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and a cd20 targeted antibody |
| KR20240024047A (ko) | 2021-04-08 | 2024-02-23 | 아티바 바이오테라퓨틱스, 인크. | Nk 세포와 cd38 표적 항체를 이용한 암 치료 방법 |
| CN117529327A (zh) * | 2021-04-08 | 2024-02-06 | 埃迪瓦生物治疗公司 | 用nk细胞和靶向cd20的抗体治疗肿瘤 |
| CN117715647A (zh) * | 2021-04-08 | 2024-03-15 | 埃迪瓦生物治疗公司 | 用nk细胞和cd38靶向抗体治疗癌症 |
| US20240366664A1 (en) * | 2021-04-08 | 2024-11-07 | Artiva Biotherapeutics, Inc. | Treatment of cancer with nk cells and an egfr targeted antibody |
| US20240197783A1 (en) * | 2021-04-21 | 2024-06-20 | Indapta Therapeutics, Inc. | Methods of treatment and dosing of natural killer cell compositions |
| CN115521913B (zh) * | 2022-02-22 | 2023-07-25 | 北京景达生物科技有限公司 | NK细胞与CD20、CD38、Her2抗体联合应用 |
| CN116679065B (zh) * | 2023-07-31 | 2023-11-14 | 北京大学人民医院 | 检测试剂的应用、多发性骨髓瘤治疗预后预测方法及产品 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4889818A (en) | 1986-08-22 | 1989-12-26 | Cetus Corporation | Purified thermostable enzyme |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US6016891A (en) | 1998-08-10 | 2000-01-25 | Sava; John G. | Tree stand harness system |
| JP2008500832A (ja) * | 2004-06-01 | 2008-01-17 | サントル・オスピタリエ・レジオナル・エ・ユニヴェルシタイル・ドゥ・トゥール | Ｆｃｇｒ３ａゲボタイプ（ｇｅｂｏｔｙｐｅ）および非枯渇性抗体に対する処置応答を評価するための方法 |
| ES2678094T3 (es) * | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| WO2009041113A1 (ja) * | 2007-09-28 | 2009-04-02 | Olympus Corporation | Fc受容体遺伝子導入ＮＫ細胞、その作製方法、及びこれを用いた抗体依存性細胞障害のアッセイ方法 |
| WO2012061814A1 (en) | 2010-11-05 | 2012-05-10 | Transgenomic, Inc. | Pcr primers and methods for rapid and specific genotyping |
| US10066207B2 (en) * | 2012-04-18 | 2018-09-04 | Board Of Trustees Of Michigan State University | Natural killer cells with enhanced immune response |
| US10813952B2 (en) * | 2014-11-14 | 2020-10-27 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors |
| AU2018219895C1 (en) * | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
-
2019
- 2019-05-14 CN CN201980045391.XA patent/CN112839666A/zh active Pending
- 2019-05-14 EP EP24194391.9A patent/EP4474391A3/en not_active Withdrawn
- 2019-05-14 US US17/054,496 patent/US20210187025A1/en not_active Abandoned
- 2019-05-14 EP EP19803497.7A patent/EP3793573B1/en active Active
- 2019-05-14 WO PCT/US2019/032318 patent/WO2019222293A1/en not_active Ceased
- 2019-05-14 JP JP2020564137A patent/JP2021522839A/ja active Pending
- 2019-05-14 DK DK19803497.7T patent/DK3793573T3/da active
- 2019-05-14 AU AU2019271146A patent/AU2019271146A1/en not_active Abandoned
- 2019-05-14 PT PT198034977T patent/PT3793573T/pt unknown
- 2019-05-14 CA CA3099806A patent/CA3099806A1/en active Pending
- 2019-05-14 ES ES19803497T patent/ES2993360T3/es active Active
-
2024
- 2024-04-18 JP JP2024067406A patent/JP2024096956A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12466871B2 (en) | Fusion protein for use in the treatment of HVG disease | |
| Jin et al. | CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers | |
| Wu et al. | Clonal expansion and compartmentalized maintenance of rhesus macaque NK cell subsets | |
| Levy et al. | Natural killer cells in human cancer: from biological functions to clinical applications | |
| JP2022515290A (ja) | 改変ｔ細胞、その調製方法および使用 | |
| JP7584437B2 (ja) | 抗ｂｃｍａ ｃａｒ ｔ細胞の製造 | |
| AU2018342245A1 (en) | Methods of isolating T cells having antigenic specificity for a p53 cancer-specific mutation | |
| US20220289849A1 (en) | Car for use in the treatment of hvg disease | |
| JP2016509840A5 (enExample) | ||
| JP2020507349A5 (enExample) | ||
| CN106434552B (zh) | 新型nkt样细胞亚群及其治疗肿瘤的用途 | |
| WO2020210365A1 (en) | Dnmt3a knock-out and stat5 activated genetically engineered t-cells | |
| CN107002036A (zh) | 用于建立具有编码抗原特异性t细胞受体的基因的多能性干细胞的方法 | |
| TW202102667A (zh) | 用於擴增和分化供過繼性細胞治療之ｔ淋巴細胞和天然殺手（ｎｋ）細胞之方法 | |
| CN117355327A (zh) | 表达用于下调mhc i类和ii类表达的嵌入人工微rna中的shrna的car nkt | |
| KR20230022868A (ko) | 재조합 수용체를 발현하는 공여자-배치 세포의 제조 방법 | |
| Song et al. | Manufacture of CD22 CAR T cells following positive versus negative selection results in distinct cytokine secretion profiles and γδ T cell output | |
| Zhang et al. | Constitutive STAT3 signaling, in comparison with STAT5, enhances CAR T-cell efficacy and lowers systemic toxicity | |
| Kochs et al. | Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment | |
| Boje et al. | A Novel Natural Killer Cell Expansion Technology for the Development of Cellular Immunotherapies | |
| KR20260026056A (ko) | 시험관 내에서 유래된 t 세포 모집단, 이의 생성 방법, 및 사용 방법 | |
| Giannakopoulou et al. | ang, WW, Li | |
| JP2026509809A (ja) | 遺伝子改変された胎盤由来の粘膜関連不変ｔ細胞（ｍａｉｔ細胞）及びその用途 | |
| Barnkob | Role of neuropilin-1 in CD8+ T cells | |
| Harris | Bioengineering of Human Pluripotent Stem Cells for Chimeric Antigen Receptor Immunotherapy |